MORIMATSU INTL (02155) announced its annual financial results for the period ending December 31, 2025. The group recorded revenue of 6.955 billion yuan, a slight increase of 0.09% compared to the previous year. Net profit was 584 million yuan, representing a decrease of 19.95% year-on-year. Basic earnings per share were 0.49 yuan. The company stated that revenue from the pharmaceutical, biopharmaceutical, and daily chemical industries showed significant growth. The decline in revenue from certain other sectors was primarily attributed to a narrowing pace of expansion in downstream industries and a short-term slowdown in capital investment within Mainland China.